AOP-Wiki

API

All KERs

Showing 1626 to 1650 of 3129 KERs

ID	Upstream Event	Downstream Event	Creation Date	Last Updated	AOPs

2574	149: Increase, Inflammation	1376: Increase, angiogenesis	Feb 15, 2022	Dec 20, 2022	1 AOP 439: Activation of the AhR leading to metastatic breast cancer
2976	149: Increase, Inflammation	1513: General Apoptosis	Jul 31, 2023	Oct 19, 2023	1 AOP 505: Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway
3357	149: Increase, Inflammation	2265: Oligodendrocyte death, increased	Oct 1, 2024	Oct 1, 2024	1 AOP 544: Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation
3358	149: Increase, Inflammation	2266: Demyelination, increased	Oct 1, 2024	Oct 1, 2024	1 AOP 544: Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation
3764	149: Increase, Inflammation	1825: Increase, Cell death	Mar 29, 2026	Mar 29, 2026	1 AOP 472: DNA adduct formation leading to kidney failure
778	777: Increase, Inflammation (corneal cells)	778: Increase, Regenerative cell proliferation (corneal cells)	Nov 29, 2016	Dec 3, 2016	1 AOP 114: HPPD inhibition leading to corneal papillomas and carcinomas (in rat)
1440	1338: Increase, inositol triphosphate	1339: Increase, intracellular calcium	Apr 14, 2017	Apr 14, 2017	2 AOPs 214: Network of SSRIs (selective serotonin reuptake inhibitors) 226: SSRI (Selective serotonin reuptake inhibitor) to hypertension
1390	1296: Increase, insulin	1297: Activation, insulin receptor	Apr 12, 2017	Apr 12, 2017	None
3178	2119: Increase, Insulin resistance	2129: Metabolically unhealthy Obesity	Apr 9, 2024	Apr 9, 2024	1 AOP 493: ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity
3180	2119: Increase, Insulin resistance	2145: Metabolic syndrome	Apr 9, 2024	Apr 9, 2024	1 AOP 497: ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome
3721	2119: Increase, Insulin resistance	2408: Increase, Adipose lipolysis	Feb 10, 2026	Feb 10, 2026	3 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
1441	1339: Increase, intracellular calcium	1340: Activate, calmodulin	Apr 14, 2017	Apr 14, 2017	2 AOPs 214: Network of SSRIs (selective serotonin reuptake inhibitors) 226: SSRI (Selective serotonin reuptake inhibitor) to hypertension
2954	1339: Increase, intracellular calcium	2151: Disruption, neurotransmitter release	Jun 27, 2023	Apr 11, 2024	1 AOP 499: Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release
2968	1339: Increase, intracellular calcium	1262: Apoptosis	Jul 18, 2023	Apr 11, 2024	1 AOP 500: Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis
3140	1339: Increase, intracellular calcium	177: Increase, Mitochondrial dysfunction	Mar 6, 2024	Apr 11, 2024	1 AOP 500: Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis
146	134: Increase, Kupffer cell activation	209: Peptide Oxidation	Nov 29, 2016	Dec 3, 2016	None
147	134: Increase, Kupffer cell activation	276: Up Regulation, TGFbeta1 expression	Nov 29, 2016	Nov 29, 2016	None
3726	134: Increase, Kupffer cell activation	1489: Increase, Steatohepatitis	Feb 10, 2026	Feb 10, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
1477	1378: Increase, leukocyte adherence	1379: Activate, leukocyte	Apr 17, 2017	Apr 17, 2017	1 AOP 217: Gastric ulcer formation
3591	2347: Increase, Lipid degradation	459: Increase, Liver steatosis	Aug 16, 2025	Aug 16, 2025	1 AOP 591: DBDPE-induced DNA damage increase in liver leading to Non-alcoholic fatty liver disease via liver steatosis and inhibition of regeneration
3545	2332: Increase, Lipid droplet	2333: Increase, Fat mass	Jul 25, 2025	Jul 25, 2025	1 AOP 580: Mineralocorticoid Receptor Activation Leading to Increased Body Mass Index
3551	2332: Increase, Lipid droplet	2337: Increase, PLIN2	Jul 25, 2025	Jul 25, 2025	1 AOP 580: Mineralocorticoid Receptor Activation Leading to Increased Body Mass Index
1599	1445: Increase, LPO	1446: Decrease, Coupling of OXPHOS	Jun 29, 2017	Jun 29, 2017	3 AOPs 331: Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death 332: Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell growth 333: Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation
2097	1445: Increase, LPO	1772: Decrease, TAG	Apr 30, 2020	Apr 30, 2020	1 AOP 329: Excessive reactive oxygen species production leading to mortality (3)
2210	1445: Increase, LPO	1365: Increase, Apoptosis	Nov 25, 2020	Nov 25, 2020	None

Key Event Relationships (KERs)

All KERs